Amyotrophic Lateral Sclerosis (ALS)



Rehabilitative Trial With tDCS in Amyotrophic Lateral Sclerosis


Condition:   Amyotrophic Lateral Sclerosis
Interventions:   Device: Anodal bilateral motor cortex and cathodal spinal tDCS;   Device: Sham bilateral motor cortex and sham spinal tDCS
Sponsor:   Azienda Ospedaliera Spedali Civili di Brescia
Recruiting


Safety of Urate Elevation in Amyotrophic Lateral Sclerosis (ALS)


Condition:   Amyotrophic Lateral Sclerosis
Interventions:   Drug: Inosine;   Drug: Placebo
Sponsors:   Massachusetts General Hospital;   The Salah Foundation;   MGH cure ALS Fund
Not yet recruiting


A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)


Condition:   Amyotrophic Lateral Sclerosis
Interventions:   Drug: CK-2127107;   Drug: Placebo
Sponsors:   Cytokinetics;   Astellas Pharma Inc
Recruiting


Virtual Task in Amyotrophic Lateral Sclerosis


Condition:   Amyotrophic Lateral Sclerosis
Interventions:   Device: Acquisition on TouchScreen;   Device: Acquisition on Kinect;   Device: Acquisition on LeapMotion;   Device: Acquisition on TouchScreen Control Group;   Device: Acquisition on Kinect Control Group;   Device: Acquisition on LeapMotion Control Group
Sponsor:   University of Sao Paulo
Completed


Trial of Amivita in Amyotrophic Lateral Sclerosis


Condition:   Amyotrophic Lateral Sclerosis
Intervention:   Drug: Amivita
Sponsors:   Wujin People's Hospital;   Nanjing 1718 Biotech Co. Ltd
Recruiting


Amyotrophic Lateral Sclerosis: a New Paradigm


Condition:   Amyotrophic Lateral Sclerosis
Intervention:   Other: study ALS patients
Sponsor:   Conde, Bebiana, M.D.
Recruiting


Bioenergetics and Protein Metabolism in Sporadic Amyotrophic Lateral Sclerosis


Condition:   Sporadic Amyotrophic Lateral Sclerosis
Intervention:   Other: Skin Biopsy
Sponsor:   University Hospital, Angers
Not yet recruiting


Exploratory Study of Biotelemetry in Amyotrophic Lateral Sclerosis


Condition:   Amyotrophic Lateral Sclerosis
Interventions:   Device: Faros Sensor (FS) and LifeInsight Hub;   Device: Fast Fix electrode patch;   Procedure: Quantitative Measure of Speech (Core Phase Only)
Sponsor:   GlaxoSmithKline
Completed


HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS)


Condition:   Amyotrophic Lateral Sclerosis
Interventions:   Drug: Darunavir;   Drug: Ritonavir;   Drug: Raltegravir;   Drug: Zidovudine
Sponsor:   National Institute of Neurological Disorders and Stroke (NINDS)
Enrolling by invitation


Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS)


Condition:   Amyotrophic Lateral Sclerosis
Interventions:   Drug: Placebo (for MN-166);   Drug: MN-166
Sponsors:   MediciNova;   Carolinas Healthcare System
Active, not recruiting


Therapeutic Imaging Biomarkers for Amyotrophic Lateral Sclerosis


Condition:   Amyotrophic Lateral Sclerosis
Intervention:   Other: MRI
Sponsor:   University of Michigan
Active, not recruiting


Safety Study of VM202 to Treat Amyotrophic Lateral Sclerosis


Condition:   Amyotrophic Lateral Sclerosis
Intervention:   Genetic: VM202
Sponsor:   ViroMed Co., Ltd. dba VM BioPharma
Active, not recruiting


A Study to Explore the Safety and Tolerability of Acthar in Patients With Amyotrophic Lateral Sclerosis


Condition:   Amyotrophic Lateral Sclerosis
Intervention:   Drug: Repository corticotropin injection
Sponsor:   Mallinckrodt
Completed


Study of Rasagiline in Patients With Amyotrophic Lateral Sclerosis


Condition:   Amyotrophic Lateral Sclerosis
Interventions:   Drug: Rasagiline;   Drug: Placebo
Sponsor:   University of Ulm
Completed


Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis


Condition:   Amyotrophic Lateral Sclerosis
Interventions:   Drug: Ozanezumab;   Drug: Placebo
Sponsor:   GlaxoSmithKline
Completed


Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis


Condition:   Amyotrophic Lateral Sclerosis (ALS)
Interventions:   Drug: MCI-186;   Drug: Placebo;   Drug: MCI-186 in open label phase
Sponsor:   Mitsubishi Tanabe Pharma Corporation
Completed


Clinical Trial on The Use of Autologous Bone Marrow Stem Cells in Amyotrophic Lateral Sclerosis (Extension CMN/ELA)


Condition:   Amyotrophic Lateral Sclerosis
Interventions:   Procedure: Laminectomy and bone marrow stem cells transplantation;   Procedure: Intrathecal infusion of autologous bone marrow stem cells;   Procedure: Intrathecal infusion of placebo (saline solution).
Sponsors:   Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia;   Instituto de Salud Carlos III;   Hospital Universitario Virgen de la Arrixaca;   Hospital General Universitario Morales Meseguer;   Fundación Diógenes
Completed


Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)


Condition:   Amyotrophic Lateral Sclerosis
Interventions:   Drug: Olesoxime;   Drug: Placebo Comparator
Sponsors:   Trophos;   European Commission
Completed


A Multi-Center Controlled Screening Trial of Safety and Efficacy of Lithium Carbonate in Subjects With Amyotrophic Lateral Sclerosis (ALS)


Condition:   Amyotrophic Lateral Sclerosis
Intervention:   Drug: lithium carbonate
Sponsors:   Forbes Norris MDA/ALS Research Center;   Muscular Dystrophy Association
Unknown status


Phase II/III Randomized, Placebo-controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral Sclerosis


Condition:   Amyotrophic Lateral Sclerosis
Interventions:   Drug: Arimoclomol;   Drug: Placebo
Sponsors:   University of Miami;   Massachusetts General Hospital
Completed


A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS)


Condition:   Amyotrophic Lateral Sclerosis (ALS)
Intervention:   Drug: E0302 (mecobalamin)
Sponsor:   Eisai Co., Ltd.
Completed


Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (ALS)


Condition:   Amyotrophic Lateral Sclerosis (ALS)
Interventions:   Drug: MCI-186;   Drug: Placebo of MCI-186
Sponsor:   Mitsubishi Tanabe Pharma Corporation
Completed


Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity Classification III


Condition:   Amyotrophic Lateral Sclerosis (ALS)
Interventions:   Drug: MCI-186;   Drug: Placebo of MCI-186
Sponsor:   Mitsubishi Tanabe Pharma Corporation
Completed


Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS)


Condition:   Amyotrophic Lateral Sclerosis (ALS)
Interventions:   Drug: MCI-186;   Drug: Placebo of MCI-186
Sponsor:   Mitsubishi Tanabe Pharma Corporation
Completed


Early Treatment of Amyotrophic Lateral Sclerosis (ALS) With Nutrition and Non-Invasive Positive Pressure Ventilation (NIPPV)


Condition:   Amyotrophic Lateral Sclerosis
Intervention:   Device: BiPAP
Sponsors:   University of Kentucky;   National Institute of Neurological Disorders and Stroke (NINDS)
Unknown status

Refine Your Search Advanced Search